Latest News

Filters

Filter by tags: Radiopharmaceutical Clear all tag filters

20 news articles found

Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.

Source: NEI Magazine
Date: Friday, 27 January 2023
Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229

The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.

Source: World Nuclear News
Date: Wednesday, 25 January 2023
Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p

Rosatom has launched a trial operation of the first industrial facilities at the Centre for Nuclear Research and Technology (CNRT) under construction in El Alto, Bolivia, the world’s highest altitude nuclear centre situated 4,000 metres above sea level. A ceremony was held to marking trial operation the first industrial facilities of the CNRT - the preclinical cyclotron-radiopharmacological complex (PCRC) and the multipurpose irradiation centre (MCC). The event was attended by CEO of the Bolivian Atomic Energy Agency Ortesia Jimenez and President of JSC Rusatom Overseas Evgeny Pakermanov.

Source: NEI Magazine
Date: Saturday, 13 August 2022
Original article: neimagazine.com/news/newstrial-operation-begins-at-bolivias-nuclear-research-and-technology-centre-9924570

Bruce Power and Kinectrics-Framatome joint venture Isogen are examining the feasibility of producing the medical radioisotope yttrium-90 using the innovative Isotope Production System (IPS) installed in unit 7 at Bruce Power's nuclear power plant in Ontario.

Source: World Nuclear News
Date: Wednesday, 29 June 2022
Original article: world-nuclear-news.org/Articles/Bruce-Power,-Isogen-look-to-build-on-radioisotope

Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.

Source: World Nuclear News
Date: Thursday, 23 June 2022
Original article: world-nuclear-news.org/Articles/Canadian-Candu-produces-cancer-therapy-isotope

Australia’s Radiopharm Theranostics and US-based TerraPower have announced an agreement to advance the next generation of radiopharmaceutical therapies for cancer treatment.

Source: NEI Magazine
Date: Thursday, 10 February 2022
Original article: neimagazine.com/news/newsradiopharm-and-terrapower-to-supply-actinium-225-9472292

The world’s highest altitude Centre for Nuclear Technology Research and Development (CNTRD) under construction by Rosatom in El Alto, Bolivia, has completed testing of its radiopharmaceuticals production line.

Source: NEI Magazine
Date: Wednesday, 05 January 2022
Original article: neimagazine.com/news/newsradiopharmaceutical-production-equipment-tested-in-bolivia-9360523

The facility will include a will include a water-cooled research reactor, an experimental gamma-installation, a cyclotron and radiopharmacology complex, engineering facilities and various laboratories. Russia’s state nuclear corporation Rosatom said it has successfully tested facilities for the production of radiopharmaceuticals at a $300m nuclear research complex in Bolivia.

According to Rosatom, radiopharmaceuticals produced at the site will be used in more than 5,000 medical procedures a year in Bolivia. Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. They can be used as diagnostic and therapeutic agents.

Rosatom said commissioning work is continuing at the facility, which will include a water-cooled research reactor with nominal power of up to 200 kW, an experimental gamma-installation, a cyclotron and radiopharmacology complex, engineering facilities and various laboratories.

Source: Nucnet
Date: Thursday, 30 December 2021
Original article: nucnet.org/news/russia-tests-production-facilities-for-radiopharmaceuticals-at-new-nuclear-research-centre-12-3-2021

ARTMS, a Canadian producer of medical isotopes has registered the cyclotron production of gallium-68 with the government of Canada, filing a Type 1 Master File with the Health Products & Food Branch of Health Canada.

Source: NEI Magazine
Date: Thursday, 28 October 2021
Original article: neimagazine.com/news/newscanadas-artms-registers-cyclotron-production-of-gallium-68-9189609

The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.

Source: World Nuclear News
Date: Thursday, 29 July 2021
Original article: world-nuclear-news.org/Articles/Viewpoint-Nuclear-medicine-is-crucial-for-fighting

Load more news